BOULDER, Colo., Nov. 6, 2018 /PRNewswire/ -- Array BioPharma
Inc. (Nasdaq: ARRY) today announced that its Chief Executive
Officer, Ron Squarer, will speak at
the Stifel 2018 Healthcare Conference and the Jefferies 2018 London
Healthcare Conference. The public is welcome to participate in the
conferences through webcasts on the Array BioPharma
website.
Event:
|
Stifel 2018
Healthcare Conference
|
Presenter:
|
Ron Squarer, Chief
Executive Officer, Array BioPharma
|
Date:
|
Tuesday, November 13,
2018
|
Time:
|
3:30 p.m. Eastern
Time
|
Webcast:
|
http://wsw.com/webcast/stifel14/arry/
|
|
|
Event:
|
Jefferies 2018 London
Healthcare Conference
|
Presenter:
|
Ron Squarer, Chief
Executive Officer, Array BioPharma
|
Date:
|
Thursday, November
15, 2018
|
Time:
|
9:00 a.m. Eastern
Time
|
Webcast:
|
http://wsw.com/webcast/jeff115/arry/
|
About Array BioPharma
Array BioPharma Inc. is a
fully-integrated, biopharmaceutical company focused on the
discovery, development and commercialization of transformative and
well-tolerated targeted small molecule drugs to treat patients
afflicted with cancer and other high-burden diseases. Array markets
in the United States
BRAFTOVI® (encorafenib) capsules in combination with
MEKTOVI® (binimetinib) tablets for the treatment of
patients with unresectable or metastatic melanoma with a
BRAFV600E or BRAFV600K
mutation. Array's lead clinical programs, encorafenib and
binimetinib, are being investigated in over 30 clinical trials
across a number of solid tumor indications, including a Phase 3
trial in BRAF-mutant colorectal cancer. Array's pipeline
includes several additional programs being advanced by Array or
current license-holders, including the following programs currently
in registration trials: selumetinib (partnered with AstraZeneca),
larotrectinib and LOXO-292 (partnered with Loxo Oncology),
ipatasertib (partnered with Genentech), tucatinib (partnered with
Seattle Genetics) and ARRY-797. Ganovo® (danoprevir,
partnered with Roche) was recently approved in China for the treatment of viral hepatitis C.
For more information on Array, please visit www.arraybiopharma.com
or follow @arraybiopharma on Twitter and LinkedIn.
CONTACT:
Andrea N. Flynn, Ph.D.
Senior Director, Investor Relations & Corporate
Communications
(303) 381-6600
ir@arraybiopharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-present-at-the-stifel-2018-healthcare-conference-and-the-jefferies-2018-london-healthcare-conference-300744231.html
SOURCE Array BioPharma Inc.